___

• [1] Coles A., Compston A., 2008. Multiple sclerosis, [abstract]. The Lancet, 372(9648), 1502-1517.
• [2] Ghasemi N., Nikzad E., Razavi S., 2017. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, [abstract]. Cell Journal, 19(1), 1-10.
• [3] Khare M., Singh A.V., Zamboni P., 2014. Prospect of Brain-Machine Interface in Motor Disabilities: The Future Support for Multiple Sclerosis Patient to Improve Quality of life. Annals of Medical and Health Sciences Research, 4(3), 305-312.
• [4] Goodin D.S., Hauser S.L., 2008. Multiple Sclerosis and Other Demyelinating Diseases. Harrison's Principles of Internal Medicine. 17th ed. McGraw-Hill Medical. New York, USA, 2611-2621.
• [5] Archelos J.J., Hartung H.P., Hemmer B., 2002. New concepts in the immunopathogenesis of multiple sclerosis. Nature Reviews Neuroscience, 3(4), 291- 301.
• [6] Carrieri P.B., Delfino M., Gattoni A., Montella S., Petracca M., Sepe C., 2008. Multiple sclerosis and systemic sclerosis: efficacy of interferon beta on skin lesions. Annals of the Rheumatic Diseases, 67(8), 1192-1193.
• [7] Krupp L.B., 2003. Fatigue in Multiple Sclerosis: Definition, Pathophysiology and Treatment. CNS Drugs, 17(4), 225-234.
• [8] Ascherio A., Munger K.L., 2007. Environmental risk factors for multiple sclerosis, Part I: the role of infection. Annals of Neurology, 61(4), 288-299.
• [9] Mowry E.M., 2011. Natural history of multiple sclerosis: early prognostic factors. Neurologic Clinics, 29(2), 279-292.
• [10] Confavreux C., Vukusic S., 2007. Natural history of multiple sclerosis: risk factors and prognostic indicators. Current Opinion in Neurology, 20(3), 269-274.
• [11] Lublin F.D., 2005. Clinical features and diagnosis of multiple sclerosis. Neurologic Clinics, 23(1), 1-15.
• [12] Garriga J.S., Jordana A.V., Tintore M., 2019. Treatment of multiple sclerosis: success from bench to bedside, [abstract]. Nature Reviews Neurology, 15(1), 53-58.
• [13] Akpolat T., Arık N., Karaaslan Y., Turgan Ç., 1991. Plazmaferez ve renal hastalıklarda kullanımı. Türk İlaç ve Tedavi Dergisi, 4, 557-561.
• [14] Hakim R.M., Siami G.A., 1994. Plasmapheresis. Handbook of Dialysis. Daugirdas JT, Ing TS (eds). Little, Brown and Company, Boston, USA, 218-241.
• [15] Al-Kutoubi A., Barada W., El-Hajj T., Hourani R., Salti H., Yamout B., … , Bazarbachi A., 2010. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study, [abstract]. Journal of Neuroimmunology, 227(1-2), 185-9.
• [16] Getts D.R., Harp C.T., Hunter Z., McCarthy D.P., Miller S.D., Shea L.D., Yap W.T., 2014. A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease. ACS Nano, 8(3), 2148-2160.
• [17] Banerji T., Calkins E., Chaudhary P., Hartley M.D., Kirkemo L.L., Tagge I.J., … ,Scanlan T.S., 2019. Myelin repair stimulated by CNS-selective thyroid hormone action. JCI Insight, 4(8), e126329.
• [18] Cekanaviciute E., Debelius J.W., Nelson C.A., Runia T.F., Singh S., Yoo B.B., … ,Baranzini S.E., 2017. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 114(40), 10713-10718.
• [19] Eccles J.D., Keyes T.J., Louveau A., Peske J.D., Rouhani S.J., Smirnov I., … ,Kipnis J., 2015. Structural and functional features of central nervous system lymphatic vessels, Nature, 523, 337-41.
• [20] Brück W., Lassmann H., Lucchinetti C.F., 2007. The immunopathology of multiple sclerosis: an overview, [abstract]. Brain Pathology, 17(2), 210-8.
• [21] Lässer C., Mohammadi M.R., Pone E.J., Riazifar M., Segaliny A.I., Yeri A., … ,Zhao W., 2019. Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. ACS Nano, 13(6), 6670-6688.
• [22] Vidal J.J., 1973. Toward direct brain-computer communication. Annual Review of Biophysics and Bioengineering, 2, 157-80.
• [23] Birbaumer N., McFarland D.J., Pfurtscheller G., Vaughan T.M., Wolpaw J.R., 2002. Brain-computer interfaces for communication and control. Clinical Neurophysiology, 113(6), 767-91.
• [24] Allison B.Z., Bauernfeind G., Brunner C., Pfurtscheller G., Scherer R., Solis-Escalante T., …,Birbaumer N., 2010. The hybrid BCI. Frontiers in Neuroscience, 4, 3.
• [25] Lin L.N., Liu F.F., Liu Q., Sha J.X., Song L., 2010. Recent advances in nanotechnology based drug delivery to the brain. Cytotechnology, 62(5), 377-380.
• [26] Kanwar J.R., Mohan R.R., Punj V., Sriramoju B., Sun X., Zhou S.F., … ,Kanwar R.K., 2012. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal, [abstract]. Nanomedicine, 8(4), 399-414.
• [27] Gailite L., Gianfelice A., Lenardi C., Milani P., Singh A.V., 2009. A simple lift-off-based patterning method for micro-and nanostructuring of functional substrates for cell culture. Journal of Micromechanics and Microengineering, 19(11), 115028.
• [28] Forti S., Gailite L., Lenardi C., Matteoli M., Milani P., Singh A.V., Vyas V., 2011. Rapid prototyping of nano- and micro-patterned substrates for the control of cell neuritogenesis by topographic and chemical cues. Materials Science and Engineering:C, 31(5), 892-899.
• [29] Calafoire R., Chang T.M.S., Gascón A.R., Hernández R.M., Orive G., Vos P.D., … , Pedraz J.L., 2003. Cell encapsulation: promise and progress. Nature Medicine, 9(1), 104-7.
• [30] Fernandes R., Gracias D.H., 2012. Self-folding polymeric containers for encapsulation and delivery of drugs. Advanced Drug Delivery Reviews, 64(14), 1579-1589.
• [31] Ausländer S., Fussenegger M., Wieland M., 2012. Smart medication through combination of synthetic biology and cell microencapsulation. Metabolic Engineering, 14(3), 252-60.
• [32] Falamarzian A., Garg S.M., Lavasanifar A., Xiong X.B., 2011. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. Journal of Controlled Release, 155(2), 248-61.
• [33] Anitua E., Emerich D. F., Orive G., Pedraz J.L., 2009. Biomaterials for promoting brain protection, repair and regeneration. Nature Reviews Neuroscience, 10(9), 682-92.
• [34] Desimone J.M., Petros R.A., 2010. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615-27.
• [35] Gemmati D., Milani P., Singh A.V., Subhashree L., Zamboni P., 2010. Review:Interplay of iron metallobiology, metalloproteinases, and FXIII, and role of their gene variants in venous leg ulcer. The International Journal of Lower Extremity Wounds, 9(4), 166-79.
• [36] Gutowski N.J., Holley J.E., Newcombe J., Whatmore J.L., 2010. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neuroscience Letters, 470(1), 65-70.
• [37] Dijkstra C.D., Horssen J.V., Vries H.E.D., 2007. The extracellular matrix in multiple sclerosis pathology. Journal of Neurochemistry, 103(4), 1293-1301.
• [38] Bicknell R., Neri D., 2005. Tumour vascular targeting. Nature Reviews Cancer, 5(6), 436-446.
• [39] Lin K.Y., Maltzahn G.V., Mesters R., Park J.H., Schwöppe C., Singh N., … ,Bhatia S.N., 2011. Nanoparticles that communicate in vivo to amplify tumour targeting. Nature Materials, 10(7), 545-552.
• [40] Gade W.N., Khare M., Singh A.V., Zamboni P., 2012. Theranostic Implications of Nanotechnology in Multiple Sclerosis: A Future Perspective. Autoimmune Diseases, 2012, 12.
• [41] Huang Y.M., Link H., 2006. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness Journal of Neuroimmunology, 180(1-2), 17-28.
• [42] Stoeckli E.T., 2012. What does the developing brain tell us about neural diseases? European Journal of Neuroscience, 35(12), 1811-1817.
• [43] Hassan S., Singh A.V., 2014. Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine. Journal of Nanoscience and Nanotechnology, 14(1), 402-414.
• [44] Cortelli D., Dellasega D., Podestà A., Salve T.S., Singh A.V., Vyas V., … ,Gade W.N., 2012. Biofilm formation on nanostructured titanium oxide surfaces and a micro/nanofabrication-based preventive strategy using colloidal lithography. Biofabrication, 4(2), 2484-2490.
• [45] Kumar B., Ojha S., 2018. A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis. Journal of Cellular Immunotherapy, 4(2), 56-64.
• [46] Certo A., McKay C.A., Pace F., Raymond M., Singh A.V., Zuidema J.M., … ,Wan L.Q., 2015. Astrocytes increase ATP exocytosis mediated calcium signaling in response to microgroove structures. Scientific Reports, 5(1), 7847.
• [47] Han L., Kong D.K., Ma C., Murikinati S., Yuan P., Zheng M.Q., … ,Zhou J., 2016. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano, 10(4), 4209-4218.
• [48] Choonara Y.E., Kumar P., Modi G., Pillay V., 2016. Improving drug delivery technology for treating neurodegenerative disease. Expert Opinion on Drug Delivery, 13(7), 1029-1043.
• [49] Hosseinidoust Z., Park B.W., Singh A.V., Sitti M., Yasa O., 2017. Microemulsion Based Soft Bacteria Driven Microswimmers for Active Cargo Delivery. ACS Nano, 11(10), 9759-9769.
• [50] Gidwani M., Singh A.V., 2014. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges. Current Pharmaceutical Biotechnology, 14(14), 1201-1212.
• [51] Lovley D.R., Walker D.J.F., 2019. Geobacter Protein Nanowires. Frontiers in Microbiology, 10, 2078.